Bone Marrow Stromal Cell Antigen 2 (BST2), a transmembrane glycoprotein initially identified as HM1.24 and later referred to as BST2 or CD317, has gained attention due to its elevated levels in multiple myeloma reported in 1994 [18]. Here, BST2 is linked to plasma cell myeloma.